Seridopidine

Seridopidine (INNTooltip International Nonproprietary Name; developmental code name ACR343) is a dopamine D₂ receptor modulator and so-called "dopaminergic stabilizer" which is or was under development for the treatment of Parkinson's disease and Tourette's syndrome.^[1][2][3][4] It is taken orally.^[1] The drug is or was under development by Carlsson Research AB, NeuroSearch, and Saniona.^[1][2] As of June 2019, no recent development has been reported for Parkinson's disease or Tourette's syndrome.^[1] The drug has reached phase 1 clinical trials for both indications.^[1][3] It entered phase 1 trials by 2008.^[3] Seridopidine is one of the "dopidine" drugs, with the others including pridopidine (ACR-16) and ordopidine (ACR-325).^[4]

Other namesACR343; ACR-343

Routes of
administrationOral^[1]

Drug classDopamine D₂ receptor modulator

ATC code

• None

Quick facts Clinical data, Other names ...

Seridopidine

Clinical data
Other names	ACR343; ACR-343
Routes of administration	Oral[1]
Drug class	Dopamine D2 receptor modulator
ATC code	None
Identifiers
IUPAC name 1-ethyl-4-(3-fluoro-5-methylsulfonylphenyl)piperidine
CAS Number	883631-51-4
PubChem CID	11572784
DrugBank	DB19579
ChemSpider	9747554
UNII	1359K87ZYE
ChEMBL	ChEMBL3545388
CompTox Dashboard (EPA)	DTXSID90237000
Chemical and physical data
Formula	C14H20FNO2S
Molar mass	285.38 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN1CCC(CC1)C2=CC(=CC(=C2)S(=O)(=O)C)F
InChI InChI=1S/C14H20FNO2S/c1-3-16-6-4-11(5-7-16)12-8-13(15)10-14(9-12)19(2,17)18/h8-11H,3-7H2,1-2H3 Key:PHRDGRSMZPOCAB-UHFFFAOYSA-N

Close